BlackRock Health Sciences Term Trust
Last updated September 27, 2026
Organization details
- Legal name
- BlackRock Health Sciences Term Trust
- Former names
- BlackRock Health Sciences Trust II
- Ownership
- Public
- Status
- Active
- Jurisdiction of incorporation
- Maryland
- Headquarters city
- Wilmington
- Headquarters state / province
- Delaware
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BMEZ
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001785971
Board of directors
-
Arthur Philip Steinmetz · DirectorSince 2023
-
Francis C. Mahoney · DirectorSince 2026
-
Robert W. Fairbairn · DirectorSince 2025
Board connections
3 of this board's directors also sit on 35 other boards.
- via Arthur Philip Steinmetz, Francis C. Mahoney and Robert W. Fairbairn
- via Arthur Philip Steinmetz, Francis C. Mahoney and Robert W. Fairbairn
- via Arthur Philip Steinmetz, Francis C. Mahoney and Robert W. Fairbairn
- via Arthur Philip Steinmetz, Francis C. Mahoney and Robert W. Fairbairn
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
- via Arthur Philip Steinmetz and Francis C. Mahoney
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $308,421
- 4 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 30, 2026 | Liu Xiang Portfolio Manager | Option exercise | +778 | — | — |
| Jan 30, 2026 | Xie H Erin Portfolio Manager | Option exercise | +25,676 | — | — |
| Jan 30, 2026 | Liu Xiang Portfolio Manager | Sold back to the company | −778 | $15.21 | $11,832 |
| Jan 30, 2026 | Xie H Erin Portfolio Manager | Sold back to the company | −25,676 | $15.21 | $390,536 |
| Dec 19, 2025 | Robert W. Fairbairn Director | Open-market sale | −0 | $14.96 | $6 |
| Dec 19, 2025 | Robert W. Fairbairn Director | Open-market sale | −0 | $14.96 | $6 |
| Dec 18, 2025 | Robert W. Fairbairn Director | Open-market sale | −10,294 | $14.98 | $154,204 |
| Dec 18, 2025 | Robert W. Fairbairn Director | Open-market sale | −10,294 | $14.98 | $154,204 |
| Apr 21, 2025 | Weinstein Boaz 10% owner | Change of control | −20,750,913 | $14.21 | $294,870,474 |
| Jan 31, 2025 | Xie H Erin Portfolio Manager | Option exercise | +14,883 | — | — |
| Jan 31, 2025 | McClements Kyle Portfolio Manager | Option exercise | +609 | — | — |
| Jan 31, 2025 | Accettella Christopher Portfolio Manager | Option exercise | +168 | — | — |
| Jan 31, 2025 | Liu Xiang Portfolio Manager | Option exercise | +225 | — | — |
| Jan 31, 2025 | Xie H Erin Portfolio Manager | Sold back to the company | −14,883 | $16.49 | $245,414 |
| Jan 31, 2025 | McClements Kyle Portfolio Manager | Sold back to the company | −609 | $16.49 | $10,046 |
Questions about BlackRock Health Sciences Term Trust
How many directors are on BlackRock Health Sciences Term Trust's board?
BlackRock Health Sciences Term Trust's board has 3 directors: Arthur Philip Steinmetz, Francis C. Mahoney and Robert W. Fairbairn.
Are BlackRock Health Sciences Term Trust insiders buying or selling shares?
Over the last 12 months, BlackRock Health Sciences Term Trust insiders made no open-market purchases and sold $308,421 of shares in 4 sales on the open market, as reported to the SEC on Forms 4 and 5.
How is BlackRock Health Sciences Term Trust connected to…? →
Spot something wrong? Report a correction
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="blackrock-health-sciences-term-trust"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.